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Abstract
Purpose—Aurora A kinase is critical in assembly and function of the mitotic spindle. It is
overexpressed in various tumor types and implicated in oncogenesis and tumor progression. This
trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of
MLN8054, a selective small-molecule inhibitor of Aurora A kinase.
Methods—In this first-in-human, dose-escalation study, MLN8054 was given orally for 7, 14, or
21 days followed by a 14-day treatment-free period. Escalating cohorts of 3–6 patients with
advanced solid tumors were treated until DLT was seen in ≥2 patients in a cohort. Serial blood
samples were collected for pharmacokinetics and skin biopsies were collected for
pharmacodynamics.
Results—Sixty-one patients received 5, 10, 20, 30 or 40 mg once daily for 7 days; 25, 35, 45 or
55 mg/day in four divided doses (QID) for 7 days; or 55, 60, 70 or 80 mg/day plus
methylphenidate or modafinil with daytime doses (QID/M) for 7–21 days. DLTs of reversible
grade 3 benzodiazepine-like effects defined the estimated MTD of 60 mg QID/M for 14 days.
MLN8054 was absorbed rapidly, exposure was dose-proportional, and terminal half-life was
30-40 hours. Three patients had stable disease for >6 cycles.
Conclusions—MLN8054 dosing for up to 14 days of a 28-day cycle was feasible. Reversible
somnolence was dose limiting and prevented achievement of plasma concentrations predicted
necessary for target modulation. A recommended dose for investigation in phase 2 trials was not
established. A second-generation Aurora A kinase inhibitor is in development.
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The Aurora kinases are a family of serine/threonine protein kinases. Three isoforms of
Aurora kinase exist (Aurora A, B, and C), each with distinct activities. Aurora A and B have
critical roles in the normal progression of cells through mitosis, whereas Aurora C activity is
largely restricted to meiosis. Aurora A kinase localizes to centrosomes and proximal mitotic
spindles [1], where it regulates centrosome maturation/separation, the G2-M transition,
formation of mitotic spindle poles and spindles, and chromosome alignment and separation
[2-5]. Increased Aurora A kinase expression results in oncogenic transformation in
preclinical models [6-9] and has been correlated with decreased survival in patients with
solid tumors [10,11]. Aurora A kinase is amplified and overexpressed in many solid tumors
and hematological malignancies [12-16]. Consequently, Aurora A kinase is an attractive
target for anticancer treatment [17].
MLN8054 (Figure 1; Millennium, the Takeda Oncology Company) is an orally active small
molecule that selectively inhibits Aurora A kinase [18]. MLN8054 induces severe mitotic
defects, including delayed progression through mitosis, formation of abnormal mitotic
spindles and misaligned chromosomes, and chromosome segregation defects [18,19].
MLN8054 led to decreased tumor proliferation in models of human cancer grown in cell
culture and antitumor activity in human tumor xenografts including colon, prostate, and lung
cancer models [18]. The greatest efficacy was seen with once or twice daily dosing for 21
days in mice, suggesting that prolonged target inhibition results in maximal antitumor
activity. In preclinical toxicology studies, dose-limiting toxicities (DLTs) were
myelosuppression and gastrointestinal toxicity, and MLN8054 demonstrated high-affinity
binding to the alpha-1 subunit of the GABA-A receptor (Data on file, Millennium).
Preclinical pharmacokinetic/pharmacodynamic analyses suggest antitumor activity is dose-
dependent and maintenance of plasma concentrations of ~2000 nM for 8–12 hours per day is
required for efficacy in human tumor xenografts grown in mice [20].
Hepatic biotransformation of MLN8054 was studied in vitro using human liver S9 fractions
(Data on file, Millennium). Glucuronidation of the carboxylate moiety of MLN8054 to an
acyl glucuronide was the predominant mechanism of biotransformation, Hydroxylation of
the azepine moiety of MLN8054 was the major phase 1 biotransformation pathway.
Glucuronidation was mediated by UGT1 and UGT2 and hydroxylation by CYP1A2, 2C9,
2C19, 2D6, and 3A4.
This phase 1 study was conducted to: (i) determine the dose-limiting toxicity (DLT) and
maximum tolerated dose of MLN8054 when given orally for 7, 14, or 21 days, followed by
a 14-day recovery period, the latter thought to be necessary based on neutropenia results
from preclinical toxicology studies; (ii) describe the pharmacokinetics of MLN8054 from
serial blood samples; (iii) evaluate the relationship between MLN8054 exposure and




This open-label phase 1 study (NCT00249301) was conducted at 3 centers in the United
States between 19 October 2005 and 25 January 2008. The study followed the principles of
the Declaration of Helsinki. The protocol was reviewed and approved by the institutional
review board at each clinical center. Each patient provided informed written consent prior to
enrollment.
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Patients with a solid tumor malignancy refractory to conventional treatment or for which no
standard treatment existed were candidates for this study. Patients were required to be ≥18
years of age and to have an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1, expected survival greater than 3 months from study enrollment, and
adequate hematologic, renal, and hepatic function. Prior cytotoxic chemotherapy was limited
to no more than 4 regimens, and prior radiation therapy must have included less than 25% of
the hematopoietically active bone marrow. Patients were ineligible if they had central
nervous system metastases, had undergone peripheral blood stem cell or bone marrow
transplantation, or had prior gastrointestinal surgery or conditions that would impair
absorption.
Dose Escalation
The dose escalation scheme is shown in Table 1. In animal studies, dogs were the most
sensitive species to MLN8054 and the highest non-severely toxic dose in dogs was 20 mg/
m2/day. One quarter of this dose (5 mg/m2/day) was chosen as the starting dose for this first-
in-human study. Patients were enrolled in escalating dose cohorts of 3–6 patients each; if 1
of 3 patients had a DLT, the cohort was expanded to 6 patients. If 0–1 of 6 patients
experienced a DLT, then dose escalation continued. If ≥ 2 of 3–6 patients experienced a
DLT, then the MTD had been surpassed and a lower dose level or alternate schedule was
explored. Dose-escalation decisions incorporated real-time assessment of systemic drug
exposure as well as toxicity experience and utilized the Factors of 2 pharmacokinetically
guided dose-escalation method [21]. Adverse events (AEs) were defined by CTCAE version
3.0 [22]. A DLT was defined as any of the following during cycle 1: grade 4 neutropenia
lasting more than 7 days or associated with fever; grade 4 thrombocytopenia; grade 3 or
greater nausea or diarrhea that persisted despite the use of optimal anti-emetic or anti-
diarrheal therapy; any other grade 3 or greater nonhematologic AE except arthralgia/myalgia
or brief (<1 week) fatigue; or any drug-related AE requiring dose interruption or delay of
more than one week.
Patients took MLN8054 orally on an empty stomach, with nothing by mouth 2 hours before
and 1 hour after each dose except prescribed medications and water. The initial dosing
regimen was once daily for 7 days (QD-7D), with 14-day breaks (21-day cycles). Due to
somnolence with the QD regimen, the protocol was amended to include divided four-times-
daily (QID-7D) dosing, with the highest dose at bedtime. The QID administration was
designed to minimize daytime sedation (which was not observed in mice) and maximize
exposure (supported by PK computer modeling) to potentially therapeutic concentrations of
the compound [23]. In later QID cohorts, an oral psychostimulant (methylphenidate or
modafinil) was added to daytime doses (QID/M-7D) to further mitigate somnolence.
Additional cohorts received extended-duration QID/M dosing for 14-21 days per cycle
(QID/M-14D and QID/M-21D), with 14-day breaks (28- and 35-day cycles, respectively).
Adverse event information was collected throughout the study. Safety assessments were
based on evaluation of AEs and serious AEs (SAEs), including their potential relationship to
the study medication; physical examination; monitoring of clinically significant laboratory
tests, including hematologic parameters, liver function tests, and renal function tests; and
evaluation of serial electrocardiograms.
Pharmacokinetics
Blood samples for pharmacokinetic analyses were drawn once at baseline (day 1 predose),
serially on day 1 (QD dosing only—0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours postdose) and
day 7 (QD dosing—predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours postdose; QID
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dosing—before the second daily dose and 0.5, 1, 1.5, 2, 3, 4, and 6 hours postdose); and
once daily on days 8-12.
Pharmacodynamics
For patients in the QD cohorts, serial 3-mm skin punch biopsies for pharmacodynamic
analyses were obtained in a majority of patients (n = 52) at baseline and again 6 and 24
hours after the first dose of cycle 1. For patients in the QID cohorts, skin punch biopsies
were obtained at baseline and on day 7 before and 2 hours after the second daily dose of
MLN8054. The purpose of these biopsies was to detect inhibition of Aurora A kinase in
proliferating basal epithelial cells as measured by accumulation of mitotic cells.
Immunofluorescence analysis was performed on skin sections, using two mitotic markers,
pHisH3 (Cell Signalling Technologies, Danvers, MA) and MPM2 (Cell Signalling
Technologies, Danvers, MA). Skin sections were mounted with DAPI Vectashield Hard Set
Mounting Medium (Vector Laboratories, Burlingame, CA). The mitotic index was
determined by counting the number of mitotic cells per millimeter of the basal epithelial
layer.
Before receiving the first dose of MLN8054, patients underwent disease evaluation
including physical examination, computed tomography and/or magnetic resonance imaging,
and tumor markers when applicable. Evaluations were repeated after every 2 cycles of
MLN8054, and disease status was categorized using standard Response Evaluation Criteria
in Solid Tumors (RECIST) guidelines [24]. Patients who had stable disease or a partial
response continued treatment until there was evidence of disease progression or
unacceptable treatment-related toxicity. Patients who tolerated the first cycle of treatment
with MLN8054 were allowed to increase the dose of MLN8054 treatment in subsequent
cycles of treatment if the higher dose had been found to be tolerable in a subsequent cohort.
Statistical Analysis
The safety population included all patients who received at least one dose of study drug,
while the DLT population included all patients who received study drug at the assigned dose
level and had sufficient follow-up to determine if a DLT occurred. Descriptive statistics are
reported for baseline values, safety, pharmacokinetics, and pharmacodynamics.
RESULTS
Patient Characteristics
A total of 61 patients were treated in 16 dose cohorts (see Table 1) and were evaluable for
toxicity. Demographics and baseline characteristics for the safety population are shown in
Table 2. The majority of patients were male (61%) and median age was 60 years (range, 24–
80 years). All patients had a Performance Status of 0 (54%) or 1 (46%). The most common
primary diagnoses were colorectal cancer (36%), lung cancer (15%), genitourinary tumors
(13%), and sarcoma (13%). Most patients had been heavily pretreated, with 79% having
received 3 or more courses of prior treatment before study entry.
Reasons for discontinuation were progressive disease in 39 patients (64%), symptomatic
deterioration in 9 (15%), AE in 5 (8%), withdrawal of consent in 3 (5%), death of 1 (2%)
due to cardiac arrest unrelated to MLN8054, and other reasons in 4 (7%). The median
number of MLN8054 treatment cycles was 2 (range, 1–14). Patients received 98% of all
expected doses overall.
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Although 60 unique patients were enrolled in the study, 1 patient was enrolled twice and
was separately evaluated for safety as a member of both the QD-7D 40 mg cohort and the
QID-7D 25 mg cohort, and thus 61 patients were evaluable for safety. A total of 59 patients
(97%) were evaluable for DLT; the other 2 patients discontinued treatment during cycle 1,
before DLT could be evaluated. One patient in the QD-7D 5 mg cohort discontinued due to
hospitalization for renal failure and hypovolemia unrelated to MLN8054 and one patient in
the QID/M-21D 60 mg cohort discontinued due to hospitalization for spine fracture
unrelated to MLN8054.
Table 1 summarizes the observed DLTs by cohort. Somnolence, which resolved in all but
one patient, was the only DLT for MLN8054 given without methylphenidate or modafinil.
The onset of somnolence and its severity generally were correlated with dose and Cmax.
Because somnolence was thought to be related to Cmax, the dosing schedule was changed
from daily to QID dosing in an effort to lower peak plasma concentrations and allow further
dose escalation. However, dose-limiting somnolence was seen at both QD-7D dosing (1 of 6
patients at 30 mg and 2 of 4 patients at 40 mg) and QID-7D dosing (1 of 6 patients at 25 mg
and 2 of 4 patients at 55 mg).
The addition of methylphenidate (e.g. 5 mg oral dose) or modafinil repeated as needed with
the three daytime MLN8054 doses allowed further dose escalation. Dose-limiting but
reversible somnolence was seen in 1 of 6 patients in the QID/M-7D 60 mg cohort and grade
3 cognitive disorder and hallucination were experienced by 1 of 3 patients in the QID/M-7D
80 mg cohort. The QID/M-7D 80 mg cohort was not expanded to further define the MTD
using the 7-day schedule because all three patients at this level experienced grade ≥ 2 CNS
effects and the investigator consensus was to evaluate longer treatment schedules if possible.
With 14-day dosing, DLTs of reversible somnolence or other central nervous system effects
(fatigue, confusional state, and cognitive disorder) were seen in 2 of 2 patients at QID/
M-14D 70 mg. Because these events were seen during the first week of a planned 2-week
treatment, subsequent patients were enrolled to a QID/M-14D 60 mg cohort. None of 3
patients in this cohort had a DLT. Using a QID schedule with 10 mg administered 3 times
during the day and 30 mg at night, the total daily dose of 60 mg was generally tolerable over
a 7- to 14-day schedule.
Of the 4 patients who were enrolled to a QID/M-21D 60 mg cohort, 2 had a DLT. Both
patients had a DLT of somnolence and 1 of the patients also had DLTs of cognitive disorder
and confusion. Therefore, no additional cohorts were enrolled to 21-day dosing regimens.
Thus, the estimated MTD of MLN8054 was 60 mg divided QID for 7-14 days, given with
methylphenidate or modafinil as needed with the daytime doses to manage somnolence.
Adverse Events
All 61 patients (100%) were treated and were evaluable for safety. Table 3 summarizes the
most frequent drug-related adverse events, which included somnolence, fatigue, confusion,
nausea and vomiting. Forty-seven patients (77%) experienced drug-related somnolence, with
11 (18%) experiencing grade 3 somnolence. Many of the patients in this study received at
least one other medication that could have contributed to somnolence; 37 (61%) received an
opioid analgesic, 15 (25%) received a benzodiazepine or other anxiolytic, and 12 (20%)
received a hypnotic or sedative agent.
Among the 11 patients with dose-limiting somnolence related to MLN8054 across all dose
levels, concomitant use of opioid medication was reported in 8 patients. Opioid use was
reported frequently in many patients enrolled to this study, however, and the frequency of
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somnolence was comparable in patients who were or were not receiving concomitant
opioids. Moreover, dose-limiting (CTC Grade 3) somnolence was reported in 2 patients
without concomitant treatment with opioids or other sedating medications who received the
highest MLN8054 dose levels within the first days of dosing, so that further dose escalation
was not feasible even in a population not receiving concomitant opioid medications.
Thirty-four patients (56%) had a grade ≥3 AE, including 13 patients (21%) with a drug-
related grade 3 AE (Table 3); no patient had a drug-related grade 4 or 5 AE. No dose studied
was associated with grade ≥ 3 mucositis or myelosuppression, predicted to be mechanistic
effects associated with Aurora A kinase inhibition.
Nine patients (15%) died within 21 days of the last dose of MLN8054; none of these deaths
were considered drug-related.
Pharmacokinetics
Forty-eight patients (79%) had sufficient dosing and MLN8054 concentration-time data to
estimate pharmacokinetics. Mean MLN8054 plasma concentration-time profiles for QD-7D
doses are shown in Figure 2A. Pharmacokinetic parameters for each cohort are summarized
in Table 4. MLN8054 was absorbed over a short period, with Tmax ranging from 1–4 hours.
Terminal elimination half-life (t1/2) was 30–40 hours. AUC0-24 hr and Cmax were roughly
dose-proportional with QD dosing and the peak-to-trough ratio (Cmax/Cmin) for all dose
levels was approximately 5. Only 1 patient in the QD-7D 30 mg cohort had a trough
concentration on day 7 that was >2000 nM, the predicted minimum concentration needed for
inhibition of Aurora A kinase based on a tumor xenograft model [20]. The two patients with
the highest Day 1 Cmax values among PK-evaluable patients enrolled in the QD dosing
cohorts both experienced grade 3 somnolence.
The protocol was amended to implement QID-7D dosing to reduce Cmax, thereby reducing
somnolence, and to increase trough concentrations, thereby increasing the probability of
inhibiting Aurora A kinase for a substantial period of time. Using this approach with total
daily doses of 25, 35, 45, and 55 mg, the mean Cmax values were 1050, 1966, 1526, and
2484 nM, respectively, and the mean trough concentrations after the second daily dose on
day 7 were 720, 1464, 1139, and 1802 nM, respectively. The peak-to-trough ratio was
between 1.3 and 1.6 across these 4 cohorts, substantially lower than the ratio for QD dosing
regimens. On average, drug concentrations for the highest dose, QID-7D 55 mg, were close
to the target of 2000 nM.
Subsequent QID cohorts added oral methylphenidate or modafinil with each of the 3
daytime doses of MLN8054 to mitigate the impact of somnolence. Pharmacokinetic data
from the QID/M-7D 70 mg cohort showed promise for maintaining a mean plasma
MLN8054 concentration of 2000 nM and a peak-to-trough ratio of 1.65 over the course of
treatment.
When the duration of dosing was extended to QID/M-14D, both patients in the 70 mg cohort
had a DLT and neither was evaluable for pharmacokinetics. The dose level was reduced to
QID/M-14D 60 mg and all 3 patients were evaluable for pharmacokinetics. Mean MLN8054
concentrations in these patients were close to 2000 nM between the second and third doses
on day 7, and were >2000 nM between the second and third doses on day 14 (Figure 2B).
Only 1 patient in the QID/M-21D 60 mg cohort was evaluable for pharmacokinetics on days
14 and 21, and MLN8054 concentrations in this patient were <2000 nM between the second
and third doses on each of these days. Two of the 3 patients with the highest Day 7 Cmax
values among PK-evaluable patients enrolled in the various QID dosing cohorts experienced
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grade 3 somnolence. One of these patients experienced Grade 3 somnolence despite
receiving methylphenidate. Thus, of the 48 patients with sufficient data to estimate
pharmacokinetic parameters, 7 patients had trough MLN8054 concentrations that were
>2000 nM, including 1 patient in the QD-7D 30 mg cohort, 1 patient in the QID-7D 55 mg
cohort, 2 patients in the QID/M-7D 70 mg cohort, 1 patient in the QID/M-7D 80 mg cohort,
and 2 patients in the QID/M-14D 60 mg cohort.
Pharmacodynamics
Skin biopsies were evaluable pre- and post-treatment in 52 patients. Although some patient
skin samples had increased numbers of mitotic cells suggestive of Aurora A kinase
inhibition after MLN8054 dosing, these increases generally were slight and did not
compellingly indicate Aurora A inhibition in any dose cohort. No relationship was observed
between the pharmacodynamic parameters and either the MLN8054 dose or the MLN8054
pharmacokinetic parameters. Despite the fact that 7 patients had trough MLN8054
concentrations >2000 nM, the skin biopsies in these patients did not provide significant
evidence of Aurora A kinase inhibition.
Clinical Responses
No complete or partial responses were seen. Nine patients (15%) had stable disease for at
least 4 cycles, including 3 (5%) with stable disease for greater than 6 cycles. These included
1 patient in the QD-7D 5 mg cohort with colorectal cancer (8 cycles; 165 days), 1 patient in
the QID/M-7D 55 mg cohort with extraskeletal chondrosarcoma (8 cycles; 129 days), and
another patient in the QID/M-7D 55 mg cohort with spindle-cell sarcoma (12 cycles; 266
days).
DISCUSSION
As critical regulators of the mitotic process that are frequently overexpressed in human
tumors [25], the Aurora kinases have emerged as novel oncologic therapeutic targets. In
addition to kinesin spindle (Eg5 motor protein) inhibitors, polo-like kinase inhibitors, and
centromeric protein E (CENPE) inhibitors, Aurora kinase inhibitors represent a unique class
of antimitotic agents without direct anti-tubulin properties [26]. Compared to taxanes and
vinca alkaloids, Aurora kinase inhibitors may improve the therapeutic index by avoiding
neurotoxicity and specifically targeting kinases that are only expressed in dividing cells.
Several Aurora kinase inhibitors currently are in phase 1 or 2 testing [27]. Most of these are
pan-Aurora inhibitors that inhibit isoforms A, B, and C. MLN8054 is the first selective
Aurora A kinase inhibitor to enter clinical trials. Selective inhibition of Aurora A has
potential advantages because it is amplified in many solid tumors and hematological
malignancies [12-16]. Furthermore, selective Aurora A kinase inhibition may have a
different toxicity profile and therapeutic index than pan Aurora inhibitors based upon
adverse events specific to inhibiting both Aurora A and Aurora B kinase simultaneously.
This is the first reported experience with an Aurora A kinase inhibitor in clinical testing.
This novel oral compound was tolerated well at doses up to 60 mg/day in divided doses.
Escalation was halted due to dose-limiting, reversible, benzodiazepine-like somnolence and
neurocognitive changes, despite the addition of methylphenidate or modafinil in the higher
dose cohorts. MLN8054 is structurally related to the benzodiazepines and as such it has
activity against the GABAA α1 receptor. Sedation had been expected from preclinical
toxicological evaluation of MLN8054, although it was not anticipated that benzodiazepine-
like central nervous system effects would be dose limiting. Because these neurocognitive
side effects were thought to be partially dependent on peak plasma concentrations, once-
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daily dosing in the early cohorts was changed to divided daily doses in later cohorts in order
to continue dose escalation. Although some patients with somnolence received concomitant
treatment with opioids or other sedating medications, somnolence occurred with similar
frequency in patients not receiving these medications. In addition, 3 of the patients who
experienced dose-limiting somnolence (CTC Grade 3) in Cycle 1 did not receive
concomitant treatment with opioids or other sedating medications. These findings indicate
that the symptomatic somnolence seen in this study was due to MLN8054.
This phase 1 study also included pharmacokinetic analyses after the first dose in the once-
daily cohorts and at steady state (the second dose on Day 7) in the divided dosing cohorts.
MLN8054 was absorbed rapidly, with peak concentrations at 1–4 hours postdose and t1/2 of
30–40 hours. Drug exposures were roughly dose-proportional in the QD dose range
evaluated in this study. The peak-to-trough ratio was reduced from approximately 5 with
once-daily dosing to 1.3–1.6 with QID dosing.
A steady state concentration of 2000 nM, the concentration estimated to be necessary for
antitumor activity, was achieved in some but not all patients at the 60 mg dose, and in few
patients in the other dose cohorts. Skin biopsies were evaluated for mitotic arrest in the basal
epithelial cells at 24 hours—a surrogate for inhibition of Aurora A. Although some samples
had slightly increased numbers of mitotic cells, no clear relationship could be established
with either the MLN8054 dose level or MLN8054 concentration across the range of
exposures tolerable in this study. The most likely explanation is that prolonged biologically
active exposures were not achieved in the patients tested in this study, as subsequent studies
using the second-generation Aurora A kinase inhibitor MLN8237 have demonstrated dose-
dependent pharmacodynamic activity in skin biopsies obtained at similar times using
identical assays [28]. Furthermore, there was no consistent evidence of significant
myelosuppression or mucositis, the expected anti-mitotic side effects of MLN8054. By
contrast, other pan-Aurora kinase inhibitors have reported dose-related neutropenia that
defined the MTD [29,30]. No patient had a complete or partial response to the doses tested
(5–80 mg per day) for 7, 14, or 21 days with 14-day breaks, although stable disease lasting
more than 6 cycles was observed in 3 patients, including 1 at the lowest dose tested (QD-7D
5 mg) and 2 at the highest dose tested without methylphenidate or modafinil support
(QID-7D 55 mg).
In summary, benzodiazepine-like effects, especially somnolence, were DLTs of MLN8054,
despite QID dosing and the addition of an oral psychostimulant (methylphenidate or
modafinil) with daytime doses. Benzodiazepine-like toxicities were expected, but it was not
anticipated that their severity would prevent escalation to doses that provided sustained
target plasma concentrations. At the doses studied, there was no evidence of antiproliferative
effects such as myelosuppression, mucositis, or tumor response. Despite these limitations,
MLN8054 did exhibit several favorable pharmaceutical features, including reliable
absorption, dose-proportional systemic exposure, and sufficiently prolonged half life to
support a once daily administration schedules. As an anticancer agent, the MLN8054
chemotype is an oral agent distinct from the other Aurora kinase inhibitors currently in
development. Building on these results, MLN8237, a second-generation oral Aurora A
kinase inhibitor has been developed with structural modifications that are designed to
improve the risk-to-benefit profile, particularly with regard to central nervous system
effects. Clinical trials of MLN8237 are underway to evaluate the safety, pharmacokinetics,
pharmacodynamics, and clinical response in patients with advanced tumors [31,32].
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Chemical Structure of MLN8054 (Reprinted from Manfredi et al (18)). Copyright 2007
National Academy of Sciences, U.S.A.
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MLN8054 plasma concentration-time profiles. (A) Mean values in the QD-7D cohorts; (B)
Individual patients in the QID/M-14D 60 mg cohort. Open symbols = mean values; closed
symbols = individual data.
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